The Point of Care Diagnostics Market size is projected to reach US$ 88.83 billion by 2031 from US$ 37.93 billion in 2024. The market is estimated to register a CAGR of 13.0% during 2024–2031. The Integration Of Artificial Intelligence (AI) and Machine Learning (ML) is likely to bring new trends to the market in the coming years.

Point of Care Diagnostics Market Analysis

The Point of Care (POC) Diagnostics Market growth is driven by the increasing prevalence of infectious diseases, which has heightened the demand for rapid and accurate diagnostic solutions. Technological advancements and the integration of artificial intelligence and machine learning are enhancing the efficiency and accuracy of testing methods. Additionally, the growing need for self-diagnostic tools and the shift toward decentralized healthcare are expected to create future opportunities for market expansion. However, challenges such as the standardization between POC testing and centralized laboratory methods impact the broader adoption of these diagnostic solutions.

Point of Care Diagnostics Market Overview

The Point of Care (POC) Diagnostics Market is evolving, with the increasing demand for immediate and accurate diagnostic solutions. POC testing is conducted near the site of patient care, allowing for quick results that facilitate timely decision-making in clinical settings. This demand for this testing is influenced by the rising prevalence of infectious diseases and chronic conditions, which necessitate rapid diagnostic capabilities.

Innovations such as portable diagnostic devices and integrated digital health solutions enhance testing efficiency and accessibility. The shift toward decentralized healthcare models propels patients and healthcare providers to seek more convenient testing options that can be performed outside traditional laboratory settings.

Overall, the POC diagnostics market is poised for substantial growth, driven by the need for rapid testing solutions and the ongoing advancements in diagnostic technologies.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Point of Care Diagnostics Market: Strategic Insights

Market Size Value in	US$ 36,000.4 Million in 2021
Market Size Value by	US$ 82,958.3 Million by 2028
Growth rate	CAGR of 12.7% from 2021-2028
Forecast Period	2021-2028
Base Year	2021

Mrinal

Have a question?

Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

 Speak to Analyst

Point of Care Diagnostics Market Drivers and Opportunities

Key Product Launches and Developments 

The number of point-of-care tests has increased since its introduction. It is expected to grow with new product launches intended at delivering inexpensive care at the facilities at the closest possible distance from the patients' location. New products or technologies are being introduced to enhance the effectiveness of devices with incremental improvements in analytical performance. The growth of the point of care diagnostics market is driven by the introduction of new devices to perform molecular tests. New devices launched in the recent years include:

• In June 2023, Sysmex Corporation launched a point-of-care testing system in Europe to detect antimicrobial susceptibility. The system identifies the presence or absence of bacteria and evaluates the effectiveness of antimicrobials using patient urine samples suspected of having UTIs.

• In January 2023, Cipla Limited launched Cippoint, a point-of-care testing device. This device provides testing parameters such as cardiac markers, infectious diseases, diabetes, fertility, thyroid function, inflammation, metabolic markers, and coagulation markers. The device is CE IVD approved, which indicates that the device is approved by the European In-Vitro Diagnostic Device Directive, providing reliable testing solutions.

• In July 2021, QuantuMDx launched the Q-POC rapid PCR point-of-care diagnostic system, with its first test, a SARS-CoV-2 detection assay, now CE-IVD marked for use in Europe under the In Vitro Diagnostics Directive (98/79/EC).

Thus, increasing product launches by the market players propels the growth of the POC diagnostics market.

Rising Product Launches and Advancements by Market Players in Emerging Economies

For business expansion, market players are focusing on emerging nations, such as India, China, and Brazil, due to the large population suffering from HIV and other infectious diseases. According to the Press Information Bureau 2023 report, ~2.5 million people are living with HIV in India, with a prevalence rate of 0.2%, and 66,400 new HIV infections are reported in India annually. The increasing product launches indicate a potential environment for the adoption of advanced point-of-care diagnostic kits. In January 2022, Mylab launched the CoviSwift POC testing solution in India, which can be used in small labs, in-hospital labs, airports, and villages and allows gold-standard testing at high throughputs anywhere. The solution encompasses the CoviSwift assay and Compact-Q machines that process 16 samples within 40 minutes, which is approximately 4 times faster than traditional RT-PCR testing while maintaining high precision.

Advancements in nanotechnology and genomics are increasing the demand for diagnostics in the healthcare sector, encouraging the introduction of a greater number of point-of-care test systems and facilitating the shift toward personalized medicine. There are new opportunities in infectious disease testing, molecular oncology, and pharmacogenomics in emerging countries. The development of nanomaterials and nanotechnology has promoted the progress of POCT platforms, which are used in colorimetric, optical, electrochemical, magnetic, and catalytic approaches. The point of care testing platforms are used to detect nucleic acids, proteins, pesticides, viruses, bio-markers in disease diagnosis, and even heavy-metal species. Thus, rising product launches and advancements in emerging countries are anticipated to provide ample growth opportunities for the point-of-care diagnostics market during the forecast period.

Point of Care Diagnostics Market Report Segmentation Analysis

Key segments that contributed to the derivation of the Point of Care Diagnostics Market analysis are product, purchase mode, sample, end user, and geography.

• Based on product, the point of care diagnostics market is segmented into glucose monitoring, infectious disease testing, cardiometabolic testing, pregnancy and fertility testing, coagulation testing, tumor/cancer marker testing, cholesterol testing, urinalysis testing, hematology testing, thyroid testing, and others. The glucose monitoring segment held the largest share of the point of care diagnostics market in 2024, and it is expected to register a significant CAGR during 2024–2031.
• By purchase mode, the market is categorized into OTC and prescription. The prescription segment held a larger share of the point of care diagnostics market in 2024.
• As per sample, the point of care diagnostics market is segmented into blood, urine, and others. The blood segment held the largest share of the point of care diagnostics market in 2024, and it is expected to register a significant CAGR during 2024–2031.
• Per end user, the Point of Care Diagnostics Market is segmented into healthcare facilities, homecare, and others. The healthcare facilities segment held the largest share of the Point of Care Diagnostics Market in 2024, and it is expected to register a significant CAGR during 2024–2031.

Point of Care Diagnostics Market Share Analysis by Geography

The geographic scope of the Point of Care Diagnostics Market report is mainly divided into five major regions: North America, Europe, Asia Pacific, the Middle East and Africa, and South and Central America. North America region is leading the market due to its robust healthcare infrastructure and early adoption of innovative diagnostic technologies. Canada ranks eighth among the largest medical device markets. According to the Government of Canada 2023 report, the prevalence of diabetes is rising at a significant pace. ~3.7 million population of the country (which is 9.4% of the total population) are living with diabetes or prediabetic conditions. The association has stated that every three minutes, a person is diagnosed with diabetes. Additionally, according to a report published by the government of Canada, the prevalence of HIV in Canada has grown by ~35.2% since 2022, and 2,434 new HIV cases reported in 2023. As per the Canadian Cancer Society, cancer was one of the primary reasons for deaths in the country, as the condition caused ~30% of deaths in 2023. Lung, breast, colorectal, and prostate cancer conditions predominated the diagnoses and deaths, with more than 46% share.

In July 2023, Fortis Life Sciences, LLC acquired Toronto-based International Point of Care, Inc. (IPOC). IPOC develops and manufactures components used in diagnostics, including lyophilized reagents, membranes, recombinant proteins, and controls. With this acquisition, Fortis can provide its customers with a customizable, end-to-end solution to advance their immunodiagnostic and molecular diagnostic products. IPOC’s recently expanded 36,000 sq. ft. facility is Fortis’ third GMP and ISO 13485-compliant manufacturing site in North America. Thus, the surging prevalence of cancer, the rising incidence of other diseases, and strategic collaborations fuel the growth of the point of care diagnostics market in the country.

Digital PCR and Real-Time PCR Market Report Scope

Point of Care Diagnostics Market News and Recent Developments

The Point of Care Diagnostics Market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the key developments in the market are listed below:

• bioMérieux, a leader in the field of in vitro diagnostics, announced that it has entered into an agreement to acquire SpinChip Diagnostics ASA (“SpinChip”). This privately held Norwegian diagnostics company has developed a game-changing immunoassay diagnostics platform. The small benchtop analyzer is adapted to near patient testing as it can deliver a result from a whole blood sample within 10 minutes with the same high-sensitivity performance as the laboratory instruments. bioMérieux has held a minority stake in SpinChip since March 2024. (Source: bioMérieux, Company Website, January 2025)
• Roche announced the completion of the acquisition of LumiraDx’s Point of Care technology following the receipt of all required antitrust and regulatory clearances. Roche will now integrate the company’s multi-assay point of care platform and the related R&D, operational, and commercial sites into its global organization. (Source: Roche, Company Website, July 2024).

Point of Care Diagnostics Market Report Coverage and Deliverables

The "Point of Care Diagnostics Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:

• Point of Care Diagnostics Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
• Point of Care Diagnostics Market trends, as well as market dynamics such as drivers, restraints, and key opportunities
• Detailed PEST and SWOT analysis
• Digital PCR and real-time PCR market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the digital PCR and real-time PCR market
• Detailed company profiles